<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9478">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05696977</url>
  </required_header>
  <id_info>
    <org_study_id>0107113</org_study_id>
    <nct_id>NCT05696977</nct_id>
  </id_info>
  <brief_title>Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients</brief_title>
  <official_title>Effect of Obesity on Cyclosporine Blood Trough Level in Nephrotic Syndrome Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to assess the effect of obesity on therapeutic response and safety of&#xD;
      cyclosporine trough level in nephrotic syndrome patients and calculating a suitable&#xD;
      weight-based dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Ethical committee approval has been obtained from Ethics committee of Faculty of&#xD;
           Medicine, Alexandria University.&#xD;
&#xD;
        2. Agreement from all participants should be taken in this clinical study by assigning an&#xD;
           informed consent.&#xD;
&#xD;
        3. Nephrotic diseased patients,will be recruited from Alexandria main university hospital&#xD;
           (AMUH).&#xD;
&#xD;
        4. The 74 participants will be non-randomly assigned into 2 groups.&#xD;
&#xD;
        5. The control group is non-obese nephrotic patients with BMI &lt;25 kg/m2 will receive&#xD;
           receive Cyclosporine capsule with conventional initial dose 3 mg/kg/day using actual&#xD;
           weight.&#xD;
&#xD;
        6. The Case interventional group is Obese nephrotic patients with BMI&gt; 25kg/m2 will receive&#xD;
           Cyclosporine capsule with the best weight based dose to achieve the targeted therapeutic&#xD;
           trough level and targeted urinary protein/ creatinine ratio.&#xD;
&#xD;
        7. All patients will be subjected to :&#xD;
&#xD;
             -  First visit: Full patient history, anthropometrics (weight, hight, BMI, fat %,&#xD;
                water %, muscles% and clinical examination. Calculate the initial cyclosporine dose&#xD;
                3mg/kg/day in 2 divided doses based on actual weight.&#xD;
&#xD;
             -  Second visit after one month: blood sample withdrawal for measuring trough level,&#xD;
                lipid profile and thyroid profile, urinary sample to measure uPCR If patients don't&#xD;
                reach to targeted therapeutic trough level and targeted urinary protein/ creatinine&#xD;
                ratio,re-modifying the dose and repeat the labs after another one month in third&#xD;
                visit.&#xD;
&#xD;
             -  Finally find the best weight can be used to achieve the targeted therapeutic trough&#xD;
                level and targeted urinary protein/ creatinine ratio, and its relation with fat&#xD;
                content and lipid profile&#xD;
&#xD;
        8. The appropriate Statistical tests will be hold according to study design and parameters&#xD;
           (parametric and non-parametric) to evaluate the significance of the results.&#xD;
&#xD;
        9. Results, conclusion, discussion and recommendations will be given.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open labelled, prospective,non-randomized, two-arms,parallel groups, non-placebo controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cyclosporine level concentration and its correlation to anthropometric measures</measure>
    <time_frame>1 month</time_frame>
    <description>Measuring of Cyclosporine level in whole blood after one month of starting the drug</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine a suitable weight-based dose for obese patients</measure>
    <time_frame>1 month</time_frame>
    <description>Modifying the Cyclosporine dose according to measured trough level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring the weight as one of anthropometric measures</measure>
    <time_frame>Day 1</time_frame>
    <description>Measuring anthropometric measures as; weight in kilograms at base line of starting the Cyclosporine regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring the height as one of anthropometric measures</measure>
    <time_frame>Day 1</time_frame>
    <description>Measuring anthropometric measures as;height in metres at base line of starting the Cyclosporine regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring the BMI as one of anthropometric measures</measure>
    <time_frame>Day 1</time_frame>
    <description>Measuring anthropometric measures as; BMI (body mass index) in kilograms/meter^2 at base line of starting the Cyclosporine regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measuring some of important in-body anthropometric measures</measure>
    <time_frame>Day 1</time_frame>
    <description>Measuring anthropometric measures as;body fat percentage, body water percentage and muscle percentage content at base line of starting the Cyclosporine regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of kidney functions</measure>
    <time_frame>1 month</time_frame>
    <description>Measuring parameters represent the kidney functions including (serum creatinine in mg/dl.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of kidney functions as clearance estimation</measure>
    <time_frame>1 month</time_frame>
    <description>Measuring parameters represent the kidney functions including (estimated GFR in mL/min/1.73 mÂ²)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of kidney functions as urinary protein release</measure>
    <time_frame>1 month</time_frame>
    <description>Measuring parameters represent the kidney functions including (Urinary protein-creatinine ratio in gm/gm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile assessment</measure>
    <time_frame>1 month</time_frame>
    <description>Measuring lipid profile including (HDL, LDL,VLDL and TG) in mg/dl.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid function assessment</measure>
    <time_frame>1 month</time_frame>
    <description>Measuring Thyroid profile including (TSH, fT3, fT4 ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Covid-19 vaccine status assessment</measure>
    <time_frame>Day 1</time_frame>
    <description>Assess if the patient received Covid-19 vaccine, or not.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Nephrotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Obese nephrotic patients with BMI&gt;25 kg/m2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nephrotic obese patients receive Cyclosporine capsule initially according to weight-based dose then modifying the dose according to targeted therapeutic level.&#xD;
To determine the best weight can be used to get the targeted therapeutic level. Correlate with the lipid profile, fat percentage and other anthropometric measures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non obese nephrotic patients with BMI&lt;25 kg/m2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Nephrotic non-obese patients receive Cyclosporine capsule initially according to weight-based dose then modified dose according to targeted therapeutic level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine Capsule</intervention_name>
    <description>Determination of the most appropriate weight based dose of Cyclosporine to achieve the target therapeutic drug level and response and its relation with fat percentage and lipid profile</description>
    <arm_group_label>Non obese nephrotic patients with BMI&lt;25 kg/m2</arm_group_label>
    <arm_group_label>Obese nephrotic patients with BMI&gt;25 kg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese and overweight Nephrotic syndrome adult patients receiving Cyclosporine for more&#xD;
             than one month with prednisolone. (BMI&gt;25 kg/m2)&#xD;
&#xD;
          -  Normal or underweight individuals Nephrotic syndrome adult patients receiving&#xD;
             Cyclosporine for more than one month with prednisolone. (serving as control group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic patients liver cirrhosis (moderate to severe liver impairment)&#xD;
&#xD;
          -  Cancer patients,&#xD;
&#xD;
          -  Pregnant and lactating female patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enas A Mohamed, PharmD</last_name>
    <phone>01004344021</phone>
    <phone_ext>+2</phone_ext>
    <email>gs-enas.elkady@alexu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noha A Hamdy, PhD</last_name>
    <phone>01005182151</phone>
    <phone_ext>+2</phone_ext>
    <email>noha.alaaeldine@alexu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alexandria University</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noha A Hamdy, PhD</last_name>
      <phone>01005182151</phone>
      <phone_ext>+2</phone_ext>
      <email>noha.alaaeldine@alexu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Yasmin S Naga, PhD</last_name>
      <phone>01222244673</phone>
      <phone_ext>+2</phone_ext>
      <email>yasminenaga@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hanan M El-Goweilli, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yasmin S Naga, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Noha A Hamdy, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Enas A Mohamed, Pharm-D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>December 15, 2022</study_first_submitted>
  <study_first_submitted_qc>January 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>January 21, 2023</last_update_submitted>
  <last_update_submitted_qc>January 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cyclosporine</keyword>
  <keyword>Obese patients</keyword>
  <keyword>Lipoproteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

